SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
A More Focused Highly Defensive Index
GILD
|
|
|
<> The accompanying table [click to enlarge] includes an updated version of the ETF Innovators [ETFI] ETFI Highly Defensive PerformIdex of 36 companies based in the U.S., Canada, and Europe with market caps over $10B, which are the leaders by market cap in their defensive industry groups. This update includes a 10% reduction in the number of companies with an equal distribution of 12 each from consumer staples and healthcare, with the remaining 12 companies chosen from a variety of defensive industry groups. (A) Mass Merch>...
|
Achillion Pharma: Funding in Place to Advance HCV Pipeline
GILD
|
|
|
<> Achillion Pharma (ACHN) is a promising micro-cap biotech, specializing in the development of new treatments for infectious diseases, such as the multi-billion dollar market for the chronic treatment of hepatitis C. As I recently wrote , several companies in this space have been bought out at huge premiums over the past year – including an astounding premium of over 400% for a $57M buyout by GlaxoSmithKline (GSK) of hepatitis C virus [HCV] developer Genelabs (GNLB). Since completing a $41.5M private place>...
|
GILD
GILD
|
|
|
Solid company that shouldn't have sold off as hard as it did, I suspect accumulation
|
GILD - good
GILD
|
|
|
GILD - Got approved for Hepatitis B drugs as well as to use them on AIDS patients. The company has a very good income and lots of money to pour into research. They will continue to come out with products and should be a very good long term company. They have gone down from their 52 week high of 57.63 and are at 54.31 right now. They will probably go back up and test the 52 week high with the new news that has come out. Look to their earnings coming out over the next year - I bet they increase a fair amount.
|
Gilead Sciences
GILD
|
|
|
Speaking of strong technical setups or the last 14 years Gilead has remained in a long-term uptrend that continues to move the stock higher through both bull and bear markets. The company is best known for the drug Tamiflu and its host of HIV drugs. In 2007, more than two-thirds of Gilead's sales came from its HIV drugs. Because HIV continues to be a worldwide epidemic, the demand for Gilead drugs should remain high into the future.
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on GILD |
Visit streetinsider.com
More Resources
|